Literature DB >> 27649588

Renovascular hypertension: Effects of mesenchymal stem cells in the contralateral hypertensive kidney in rats.

Elizabeth Barbosa de Oliveira-Sales1, Vanessa Araujo Varela1, Edgar Maquigussa1, Fernanda Teixeira Borges1, Caroline Gusson Shimoura2, Guiomar Gomes2, Ruy Ribeiro Campos2, Mirian Aparecida Boim1.   

Abstract

Mesenchymal stem cells (MSC) induced neovascularization and improved renal morphology of the stenotic kidney in 2 kidneys-1 clip (2K-1C) model of renovascular hypertension. The present study evaluated the effects of MSC in the contralateral hypertensive kidney. Three weeks after left renal artery occlusion, MSC were injected into the tail vein of the 2K-1C rats. Renal function and morphology were analyzed in both kidneys. Labeled MSC were found in stenotic and contralateral kidneys. Hypertensive 2K-1C animals presented increased circulating levels of Angiotensin II (Ang II) and renin. MSC prevented the progressive increase of blood pressure and reduced circulating Ang II and renin levels. Stenotic kidney showed reduced renal plasma flow (RPF) and glomerular filtration rate (GFR), whereas the contralateral kidney had a tendency (p > 0.5) of reduction in GFR in spite of unchanged RPF. MSC treatment caused an improvement in GFR with no effect of on RPF in the stenotic kidney. Contralateral kidney showed increased diuresis and natriuresis that were even higher in MSC-treated animals, indicating that cell treatment improved the capacity of the contralateral kidney to excrete sodium. Contralateral kidney expressed higher levels of inflammatory cytokines (IL-6, TNF-α) and signs of fibrosis, which were attenuated by MSC treatment. MSC treatment improved the stenotic kidney function, and it was also beneficial to the contralateral hypertensive kidney because it improved the morphology and preserved its capacity to excrete sodium.

Entities:  

Keywords:  Mesenchymal stem cells; renal function; renin–angiotensin system; renovascular hypertension

Mesh:

Substances:

Year:  2016        PMID: 27649588     DOI: 10.3109/10641963.2016.1174253

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  6 in total

1.  Autologous Mesenchymal Stem Cells Increase Cortical Perfusion in Renovascular Disease.

Authors:  Ahmed Saad; Allan B Dietz; Sandra M S Herrmann; LaTonya J Hickson; James F Glockner; Michael A McKusick; Sanjay Misra; Haraldur Bjarnason; Adam S Armstrong; Dennis A Gastineau; Lilach O Lerman; Stephen C Textor
Journal:  J Am Soc Nephrol       Date:  2017-05-01       Impact factor: 10.121

2.  Comparison of the Effects of Mesenchymal Stem Cells with Their Extracellular Vesicles on the Treatment of Kidney Damage Induced by Chronic Renal Artery Stenosis.

Authors:  Crysthiane Saveriano Rubiao Andre Ishiy; Milene Subtil Ormanji; Edgar Maquigussa; Rosemara Silva Ribeiro; Antonio da Silva Novaes; Mirian Aparecida Boim
Journal:  Stem Cells Int       Date:  2020-10-08       Impact factor: 5.443

Review 3.  Enhancing the Therapeutic Potential of Mesenchymal Stromal Cell-Based Therapies with an Anti-Fibrotic Agent for the Treatment of Chronic Kidney Disease.

Authors:  Yifang Li; Sharon D Ricardo; Chrishan S Samuel
Journal:  Int J Mol Sci       Date:  2022-05-27       Impact factor: 6.208

4.  Mesenchymal stem cells protect renal tubular cells via TSG-6 regulating macrophage function and phenotype switching.

Authors:  Yu Zhao; Xiang-Yang Zhu; Turun Song; Lei Zhang; Alfonso Eirin; Sabena Conley; Hui Tang; Ishran Saadiq; Kyra Jordan; Amir Lerman; Lilach O Lerman
Journal:  Am J Physiol Renal Physiol       Date:  2021-02-08

Review 5.  Bone marrow-derived mesenchymal stromal cell: what next?

Authors:  Fernanda T Borges; Marcia Bastos Convento; Nestor Schor
Journal:  Stem Cells Cloning       Date:  2018-11-08

Review 6.  Cell-based regenerative medicine for renovascular disease.

Authors:  Lilach O Lerman
Journal:  Trends Mol Med       Date:  2021-06-25       Impact factor: 15.272

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.